Shield Therapeutics (STX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

2.40p
   
  • Change Today:
    -0.050p
  • 52 Week High: 5.34
  • 52 Week Low: 1.60
  • Currency: UK Pounds
  • Shares Issued: 1,041.69m
  • Volume: 336,570
  • Market Cap: £25.00m
  • Beta: 0.00

Shield Therapeutics revenue falls in line with expectations

By Josh White

Date: Thursday 17 Feb 2022

LONDON (ShareCast) - (Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics reported total 2021 revenue of £1.5m in a trading update on Thursday, in line with market expectations.
The AIM-traded firm said that consisted of net product revenue of £0.1m from US product sales, royalty revenue of £0.9m from product sales in the EU, and milestone payments of £0.5m from the upfront payment of Korea Pharma on signing the licence agreement for commercialisation in South Korea.

Cash on hand totalled £12.1m at year-end on 31 December, compared to £2.9m at the end of 2020.

On the operational front, Shield said payer coverage had increased on Accrufer since its last update in December, and was now covering 60 million commercial lives after several additional contracts were executed with the likes of Cigna, Humana, and Highmark.

It said awareness of Accrufer among target prescribers, meanwhile, had doubled since its launch, to 65%.

Healthcare professionals generated around 2,500 prescriptions for Accrufer into the firm's patient assistance and reimbursement hub since launch, with "significant growth" seen from the third to the fourth quarter.

"Our priorities for the US launch of Accrufer were to increase awareness, generate clinical experience, and expand payer coverage, and we have made significant progress across each of these priorities," said chief executive officer Greg Madison.

"We have been very pleased by the initial feedback and reactions of healthcare providers to Accrufer, and it is clear there is a need for an effective and well tolerated oral iron therapy for the millions of patients with iron deficiency."

Madison said the company would remain focussed on continuing the "strong momentum" in the US, and ensuring the group had the resources to deliver on that goal.

"We believe Accrufer [and] Feraccru has the potential to be the 'best in class' oral iron replacement product, and our efforts over the last six months have set the company up to expand access and grow sales in 2022 and beyond."

At 1533 GMT, shares in Shield Therapeutics were down 15.35% at 27.51p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

STX Market Data

Currency UK Pounds
Share Price 2.40p
Change Today -0.050p
% Change -2.04 %
52 Week High 5.34
52 Week Low 1.60
Volume 336,570
Shares Issued 1,041.69m
Market Cap £25.00m
Beta 0.00

STX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
12.36% below the market average12.36% below the market average12.36% below the market average12.36% below the market average12.36% below the market average
73.91% above the sector average73.91% above the sector average73.91% above the sector average73.91% above the sector average73.91% above the sector average
Price Trend
33% below the market average33% below the market average33% below the market average33% below the market average33% below the market average
13.04% above the sector average13.04% above the sector average13.04% above the sector average13.04% above the sector average13.04% above the sector average
Income Not Available
Growth
62.67% above the market average62.67% above the market average62.67% above the market average62.67% above the market average62.67% above the market average
80.00% above the sector average80.00% above the sector average80.00% above the sector average80.00% above the sector average80.00% above the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 2
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

STX Dividends

No dividends found

Trades for 30-May-2025

Time Volume / Share Price
16:19 10,000 @ 2.42p
16:12 80,000 @ 2.33p
15:57 42,016 @ 2.38p
15:41 5,676 @ 2.33p
14:41 6,600 @ 2.44p

STX Key Personnel

CEO Anders Lundstrom

Top of Page